Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Feb 15;207(4):553-63.
doi: 10.1093/infdis/jis726. Epub 2012 Nov 29.

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients

Stella G Muthuri  1 , Puja R Myles, Sudhir Venkatesan, Jo Leonardi-Bee, Jonathan S Nguyen-Van-Tam
Affiliations
Meta-Analysis

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients

Stella G Muthuri et al. J Infect Dis. .

Abstract

Background: The impact of neuraminidase inhibitor (NAI) treatment on clinical outcomes of public health importance during the 2009-2010 pandemic has not been firmly established.

Methods: We conducted a systematic review and meta-analysis, searching 11 databases (2009 through April 2012) for relevant studies. We used standard methods conforming to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using random effects models.

Results: Regarding mortality we observed a nonsignificant reduction associated with NAI treatment (at any time) versus none (OR, 0.72 [95% CI, .51-1.01]). However we observed significant reductions for early treatment (≤48 hours after symptom onset) versus late (OR, 0.38 [95% CI, .27-.53]) and for early treatment versus none (OR, 0.35 [95% CI, .18-.71]). NAI treatment (at any time) versus none was associated with an elevated risk of severe outcome (OR, 1.76 [95% CI, 1.22-2.54]), but early versus late treatment reduced the likelihood (OR, 0.41 [95% CI, .30-.56]).

Conclusions: During the 2009-2010 influenza A(H1N1) pandemic, early initiation of NAI treatment reduced the likelihood of severe outcomes compared with late or no treatment.

Prospero registration: CRD42011001273.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of article selection process. Abbreviation: NAI, neuraminidase inhibitor.
Figure 2.
Figure 2.
Summary of pooled analyses from studies examining mortality. Abbreviations: CI, confidence interval; NAI, neuraminidase inhibitor; OR, odds ratio.
Figure 3.
Figure 3.
Summary of pooled analyses from studies examining severe outcome. Abbreviations: CI, confidence interval; NAI, neuraminidase inhibitor; OR, odds ratio.
Figure 4.
Figure 4.
Summary of pooled analyses from studies examining A(H1N1)pdm09-associated pneumonia. Abbreviations: CI, confidence interval; NAI, neuraminidase inhibitor; OR, odds ratio.
See this image and copyright information in PMC

Comment in

References

    1. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40:42–8. - PubMed
    1. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group [erratum appears in Lancet 2000;356:1856] Lancet. 2000;355:1845–50. - PubMed
    1. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24. - PubMed
    1. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children [erratum appears in Pediatr Infect Dis J 2001 20:421] Pediatr Infect Dis J. 2001;20:127–33. - PubMed
    1. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999;44(Suppl B):23–9. - PubMed

Publication types

MeSH terms